Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
GemPharmatech Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was 2.95%.
The industry rank for GemPharmatech Co's 3-Year RORE % or its related term are showing as below:
SHSE:688046's 3-Year RORE % is ranked better than 65.89% of 1290
companies
in the Biotechnology industry
Industry Median: -11.215
vs SHSE:688046: 2.95
GemPharmatech Co (SHSE:688046) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
GemPharmatech Co 3-Year RORE % Related Terms
GemPharmatech Co 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for GemPharmatech Co's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, RVMD: 3-Year RORE % Comparison
For the Biotechnology subindustry, GemPharmatech Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
GemPharmatech Co (SHSE:688046) has a 3-Year RORE % of 2.95 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on GemPharmatech Co and its competitors. According to the industry distribution chart, GemPharmatech Co ranks #440 out of 1290 companies in the Biotechnology industry, placing it in the top 34.1%.
Is GemPharmatech Co's 3-Year RORE % too high?
GemPharmatech Co's current 3-Year RORE % is 2.95. Based on the distribution chart, GemPharmatech Co ranks #440 out of 1290 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GemPharmatech Co has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #440 out of 1290 companies for 3-Year RORE %. This puts GemPharmatech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current 3-Year RORE % is 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.81, compared to a current price of ¥33.31 — trading 68.1% above its estimated fair value. The current 3-Year RORE % is 2.95. GemPharmatech Co's overall GF Score™ is 91/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current 3-Year RORE % is 2.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥33.31 is trading 68.1% above its estimated GF Value™ of ¥19.81.
GuruFocus considers GemPharmatech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688046:
3-Year RORE %: 2.95
GF Value™: ¥19.81 vs. price of ¥33.31 (68.1% above fair value)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
91GF Score
Get the complete analysis for SHSE:688046
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
